想做制药届的AGI，「深度智耀」再获6000万美元融资｜36氪首发

Core Insights - Deep Intelligence has recently completed a $60 million financing round, bringing its total funding to over $100 million in just two months, following a $50 million round in December [1] - The funds will primarily be used for upgrading the company's core technology system, which provides a full-stack intelligent solution for drug development, from preclinical research to post-market studies [1][4] Company Overview - Deep Intelligence offers a comprehensive AI-driven solution for pharmaceutical companies, enabling them to conduct clinical trials with high precision and efficiency, achieving a "zero revision" rate for clinical trial protocols approved by regulatory bodies [1][2] - The company has developed a "bionic brain" composed of high-precision "Atomic Agents" that handle various tasks in the clinical development process, ensuring scientific validity and compliance [2][3] Technological Advancements - The system incorporates a self-reflective process that allows for continuous improvement and error correction, enhancing the accuracy of medical terminology to over 99% [3] - A new Protocol Rehearsal AI has been introduced, which simulates clinical trials to predict outcomes and optimize resource allocation, potentially transforming the drug development process from labor-intensive to intelligent decision-making [3] Investor Perspectives - Investors express strong confidence in Deep Intelligence's ability to leverage AI in clinical research, highlighting its rapid iteration of AI capabilities and its potential to reshape industry cost structures and operational models [4][5] - The company is seen as a key player in the transition from labor-intensive to intelligence-driven drug development, with expectations for significant growth in the AI and healthcare sectors [4][5]